Every 10-Q that Amylyx Pharmaceuticals (AMLX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AMLX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AMLX filings page.
Amylyx Pharmaceuticals reported Q2 2026 results showing continued investment in its rare-disease pipeline and a net loss driven by research and pre-commercial activities. Operating expenses for the quarter were $45,693 thousand, including research and development of $23,768 thousand and selling, general and administrative costs of $21,925 thousand.
The company ended June 30, 2026 with $250.8 million in cash, cash equivalents and marketable securities and states this should fund operations into 2028. Its lead asset avexitide is in the Phase 3 LUCIDITY trial for post-bariatric hypoglycemia, with last-participant 16-week visits complete and topline data expected in the third quarter of 2026. Additional programs include AMX0035 in Wolfram syndrome, AMX0114 in ALS, and AMX0318 in IND-enabling studies. Amylyx also agreed in principle to settle a securities class action for $6.5 million, with a significant portion funded by insurance proceeds, while related derivative actions remain under negotiation.
Amylyx Pharmaceuticals (AMLX) filed its Q3 2025 report, showing a smaller quarterly loss as it reorients around its clinical pipeline. Net loss was $34.4 million versus $72.7 million a year ago, with basic and diluted net loss per share of $0.37 versus $1.07. Operating expenses fell to $36.0 million from $76.1 million, reflecting the absence of prior-year charges and reduced spend on discontinued programs.
Liquidity strengthened markedly. As of September 30, 2025, cash and cash equivalents were $225.2 million and marketable securities were $118.8 million. The company completed two underwritten offerings in 2025: 19.7 million shares at $3.50 for net proceeds of $65.5 million in January and 20.1 million shares at $10.00 for net proceeds of $190.7 million in September. Shares outstanding were 109,819,569 as of October 27, 2025.
Amylyx reports no product revenue in 2025 following the RELYVRIO/ALBRIOZA discontinuation. The company is advancing key programs: the Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia (recruitment completion expected in the first quarter of 2026 with topline data in the third quarter of 2026) and the Phase 1 LUMINA trial of AMX0114 in ALS, with early cohort enrollment completed and initial data planned for scientific meetings.